Avexitide

Unassigned

New Medicines

Exendin · Post-bariatric hypoglycaemia

Information

Exendin
New molecular entity
Eiger Bio
Eiger Bio

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

GLP-1 antagonist (fragment of exenatide)
The estimated prevalence of PBH is approximately 30,000 in the United States and approximately 25,000 in the European Union [1].
Post-bariatric hypoglycaemia
Subcutaneous injection